⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5275538 | 0.80 | SLC9A1 (0.42) | — | |
| SCHEMBL5279819 | 0.77 | — | — | |
| SCHEMBL5277654 | 0.77 | SLC9A1 (0.46) | — | |
| SCHEMBL19505108 | 0.75 | — | — | |
| SCHEMBL5280866 | 0.75 | — | — | |
| SCHEMBL24377316 | 0.75 | — | — | |
| SCHEMBL5274100 | 0.75 | — | — | |
| SCHEMBL5276050 | 0.75 | — | — | |
| SCHEMBL22709095 | 0.75 | — | — | |
| SCHEMBL5275973 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010076-B1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023281479-A1 | CHECKPOINT INHIBITORS CONJUGATED TO IL-2, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2021028336-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2019191166-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018130227-A1 | AROMATIC RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | 山东罗欣药业集团股份有限公司 | 2018-07-19 | — | — | WO | disclosed |
| US-20180140595-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-05-24 | — | — | US | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-2054429-B1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA INC (CA) | 2013-11-06 | — | — | EP | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2431380-A2 | Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders | Tranzyme Pharma, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2008033328-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |